lyell.com (LYEL): Price-to-Projected Revenue Ratio

LYEL (Lyell) - company brandmark

The change in forward P/S reflects the dynamics of market revenue expectations, with the latest reading standing at 33567.90. Lyell Immunopharma (LYEL) is implementing innovations to protect T-cells from exhaustion in solid tumors. Business growth relies on alliances with oncology centers and pharmaceutical behemoths. Meanwhile, the company strictly adheres to environmental regulations regarding biohazardous waste disposal in its laboratories.

LYEL Lyell: Market Cap to Future Revenue Ratio in the range 07/04/2022 - 11/18/2026

Analytical breakdowns for Lyell Immunopharma (LYEL)

- stock price and consensus target price:
- stock exchange capitalization data:
Summary company analysis:lyell.com LYEL
Manufactured products of Lyell Pharma

For an investor in Lyell Immunopharma (LYEL), the asset's fundamental value is determined through the lens of the biopharmaceutical sector's defensive potential, which remains independent of macroeconomic fluctuations. The ratio of current market capitalization to expected sales, reflected via the forward P/S trend, enables the rapid identification of market discounts or signs of business degradation, transforming static forecasts into a dynamic tool for risk control and assessing the company's margin of safety.

Competitor analysis

ImmunityBio Inc - Forward Price-to-Revenue Multiple|Forward P/S Multiple Immunocore Corp IMCR|JANX - Price-to-Projected Revenue Ratio|RCUS (arcusbio.com) - Market Cap to Projected Revenue|Zymeworks Biopharmaceuticals (ZYME) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Tango Pharma (TNGX)|Forward Price-to-Revenue Multiple IOVA|IMTX - Projected Price to Revenue|Forward Price-to-Revenue Multiple XNCR (Xencor Corp)|Price to Expected Revenue Ratio CMPX|Forward P/S Multiple REPL (Replimune)|Forward Price to Sales IPHA|Pyxis - Forward P/S Multiple|Market Cap to Future Revenue Ratio Compugen|IO Biotech, Inc. (IOBT) - Price-to-Projected Revenue Ratio|Sutro Biopharma, Inc. - Forward Price to Sales|INKT (minktherapeutics.com) - Forward P/S Multiple|Forward P/S Multiple werewolftx.com|Price-to-Projected Revenue Ratio immixbio.com (IMMX)|ALXO: Future Price to Revenue|Forward P/S Multiple CUE (Cue Biopharma Inc.)|PDS Biotechnology (PDSB) - Market Cap to Future Revenue Ratio|SONN - Price-to-Projected Revenue Ratio|MAIA Biotechnology, Inc. (MAIA) - Forward Price-to-Revenue Multiple|LIMN: Forward P/S Multiple|LAVA Therapeutics N.V. (LVTX) - Forward P/S Multiple|Forward Price-to-Revenue Multiple NXTC|Forward P/S Multiple leaptx.com|Forward P/S Multiple INTS|Market Cap to Expected Sales Ratio Sensei Biotherapeutics, Inc.|Forward P/S Multiple TOVX (Theriva Corp)|Market Cap to Expected Sales Ratio gritstonebio.com (GRTS)|kinetabio.com - Forward P/S Multiple|NexImmune (NEXI) - Forward Price-to-Revenue Multiple|turnstonebio.com (TSBX) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Vaccinex, Inc (VCNX)|Forward Price-to-Revenue Multiple HARP